PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM CNS STIMULANT AMPHETAMINES SYMPATHOMIMETICS BLOCK THE REUPTAKE OF NOREPINEPHRINE AND DOPAMINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND NARCOLEPSY MONOAMINE TRANSPORTER BLOCKER
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM CNS STIMULANT AMPHETAMINES SYMPATHOMIMETICS BLOCK THE REUPTAKE OF NOREPINEPHRINE AND DOPAMINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND NARCOLEPSY MONOAMINE TRANSPORTER BLOCKER
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM ADRENERGIC AGENT SYMPATHOMIMETICS CAUSES THE RELEASE OF ENDOGENOUS NOREPINEPHRINE MYDRIATIC EFFECT PROVIDES DIMINISHED PUPIL RESPONSIVENESS TO LIGHT
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM SYMPATHOMIMETICS CAUSES THE RELEASE OF ENDOGENOUS NOREPINEPHRINE MYDRIATIC EFFECT PROVIDES DIMINISHED PUPIL RESPONSIVENESS TO LIGHT ADRENERGIC AGENT
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM L-LYSINE-D-AMPHETAMINE PSYCHOSTIMULANT CENTRAL NERVOUS SYSTEM STIMULANT INDICATED FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) A PRODRUG OF DEXTROAMPHETAMINE BLOCK THE REUPTAKE OF NOREPINEPHRINE AND DOPAMINE INTO THE PRESYNAPTIC NEURON AND INCREASE THE RELEASE OF THESE MONOAMINES INTO THE EXTRANEURONAL SPACE
ORAL
SOLUBILITY SOLUBLE IN WATER 792 MILLIGRAM / MILLILITER
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM SYMPATHOMIMETIC AMINE PSYCHOSTIMULANTS TREATMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY TREATMENT OF EXOGENOUS OBESITY LEADS TO THE FORMATION OF REACTIVE OXYGEN SPECIES IN THE BRAIN
ORAL
F 67.2 PERCENT (PMID8104133)
VD 242 LITER (65 KILOGRAM)
PPB 15 PERCENT
Cl 17.1 LITER / HOUR (65 KILOGRAM)
HT 12.2 HOUR
DOPAMINE TRANSPORTER (DAT) SEROTONINE TRANSPORTER
PDB4XP6 (X-RAY STRUCTURE OF DROSOPHILA DOPAMINE TRANSPORTER BOUND TO PSYCHOSTIMULANT METHAMPHETAMINE)
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex